Last reviewed · How we verify
Nevirapine, FTC, and Tenofovir
This is a fixed-dose combination of three antiretroviral drugs that work together to inhibit HIV replication through different mechanisms: reverse transcriptase inhibition and nucleotide reverse transcriptase inhibition.
This is a fixed-dose combination of three antiretroviral drugs that inhibit HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection (treatment and prevention).
At a glance
| Generic name | Nevirapine, FTC, and Tenofovir |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Drug class | Antiretroviral combination (NNRTI + NRTI + NtRI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while FTC (emtricitabine) and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs). Together, they block HIV reverse transcriptase at different binding sites and through different mechanisms, preventing the virus from converting its RNA genome into DNA and integrating into host cells. This triple-drug combination approach reduces the likelihood of resistance development.
Approved indications
- HIV-1 infection in treatment-naïve patients
- HIV-1 infection in treatment-experienced patients (with appropriate resistance testing)
Common side effects
- Rash (nevirapine-related)
- Hepatotoxicity
- Nausea
- Diarrhea
- Headache
- Renal dysfunction (tenofovir-related)
- Lactic acidosis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (PHASE2, PHASE3)
- A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nevirapine, FTC, and Tenofovir CI brief — competitive landscape report
- Nevirapine, FTC, and Tenofovir updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI